ATARA Biotherapeutics (ATRA) Misses Q3 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. META
5. MSFT
6. SPY
7. GOOGL
8. GMAB
9. USO
10. AMD

Go back to ATARA Biotherapeutics (ATRA) Misses Q3 EPS by 9c

Atara Bio Announces Third Quarter 2016 Financial Results and Recent Highlights

November 4, 2016 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today reported financial results for the third quarter ended September 30, 2016 and recent operational highlights.

We are pleased to report that for our lead product candidate, EBV-CTL, we have received feedback from FDA on our approach to comparing material manufactured by our CMO with material previously produced at MSK and have commenced manufacturing to support our Phase 3 trials, said Isaac... More